In consideration for these assets, PharmAthene has paid Avecia a cash payment of $10 million, which is subject to a post-closing working capital adjustment, and will pay an additional $7 million within eighteen months from the closing date. In addition, Avecia will be eligible to receive milestone payments totaling up to $23 million in the aggregate, contingent upon the achievement of certain milestones related to the award of contracts for development and procurement of Avecia's vaccine products by the U.S. government, and potentially royalties if certain sales levels are achieved.
In connection with the acquisition, the parties have also entered into various agreements for the transitional and longer-term supply of facilities, support and services by Avecia to PharmAthene. Among these agreements are a Master Services Agreement pursuant to which Avecia has agreed to provide process development, analytical development, production, disposition, and stability testing of vaccines for PharmAthene. Under a Supply Agreement, Avecia has agreed to manufacture and supply to PharmAthene its requirements for the rPA anthrax and plague vaccines.
On March 28, 2008, Avecia received a letter from the Defence Science
and Technology Laboratory, a branch of the UK Ministry of Defence, advising
Avecia of the recent resource allocation decision of the US Department of
Defense (DoD) that the DoD had decided not to fund Avecia's plague vaccine
candidate beyond the current contractual commitments. Based on this
development, the parties agreed to amend the sale and purchase agreeme
|SOURCE PharmAthene, Inc.|
Copyright©2008 PR Newswire.
All rights reserved